Clinical behavior of patients with lupus nephritis and metabolic syndrome versus lupus nephritis without metabolic syndrome. Clinica de la Costa, Barranquilla
DOI:
https://doi.org/10.18041/2390-0512/bioc..2.2654Keywords:
Lupus nephritis, Metabolic syndromeAbstract
Objective: Determine the clinical behavior of patients with lupus nephritis and metabolic syndrome versus lupus nephritis without metabolic syndrome. Clínica de la Costa, Barranquilla, period January-May 2015.
Materials and methods: Analytical study of cases and controls in 40 patients with lupus nephritis + association of metabolic syndrome (case group) selected controls equal number of patients with lupus nephritis without metabolic syndrome.
Results: Prevalence of metabolic syndrome 44.1%; proteinuria in 24 cases half hours was 1.2 ± 1.1 g/24 hr with 0.6 ± 0.3 g/24 hr in controls, the mean creatinine of cases was observed in 1.3 ± 0.6 mg/dl and 0.8 ± 0.3 mg/dl in controls, where creatinine clearance was 71.2 ± 38.4 ml/min to 92.7 ± 23.8 ml/min in controls.
Conclusions: There is a greater clinical involvement in patients with lupus nephritis + metabolic syndrome, compared with lupus nephritis patients without metabolic syndrome
Downloads
References
lupus erythematosus from Puerto Rico, Lupus. 2008; 17:348-54.
2. Pereira J, Luna R, Gomes L, Duarte S, Leite L, da Trindade AK et al. Lupus erythematosus: considerations about clinical, cutaneous
and therapeutic aspects. An Bras Dermarol. 2014; 89(1):118-25.
3. Anaya JM, Shoenfeld Y, Cervera R. Systemic lupus erythematosus 2014. Autoimmune Diseases. 2014; 2014:1-2.
4. Romero J, Ramírez M, González F, Díaz C, Araujo A, Rodríguez T, et al. Síndrome metabólico en lupus eritematoso sistémico. El
Residente. 2014; 9(3):116-23.
5. Cervera R, Pallares L. Epidemiología y clasificación
del lupus eritematoso sistémico. En Avances en lupus eritematoso sistémico. Cervera R, JiménezAlonso J. Barcelona: Marge
Medica Books; 2008.
6. Gómez-Puerta JA, Cervera R. Lupus eritematoso sistémico. Medicina & Laboratorio. 2008; 14(5):211-23.
7. Wallace DJ, Hahn BH, Klippel JH. Clinical and laboratory features of lupus nephritis. In: Wallace DJ, Hahn BH, editors. Dubois’Lupus
Erythematosus, 4th Ed. Philadelpia: Lippincott Williams & Wilkins; 2002; 1077-91.
8. Cameron JS. Clinical manifestations of lupus nephritis. In: Adu D, Emery P, Madaio M, editors. Rheumatology and the kidney. New
York: Oxford University Press; 2001.
9. González L, Vásquez G, Uribe O, Ramírez G. Nefropatía lúpica. Presentación clínica, clasificación y tratamiento. Rev. Colomb. Reumatol. 2006; (3)4:307-33.
10. Cervera R, Khamastha MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period. A comparison of early and late manifestations in a cohort of 1000 patients. Medicine. 2003; 82:299-308.
11. Kaur J. A comprehensive review on metabolic syndrome. Cardiology Research and Practice. 2014; 2014(1):1-22.
12. Wacher-Rodarte N. Epidemiología del síndrome metabólico. Gac Méd Méx. 2009; 145(5):384-91.
13. Instituto Colombiano de Bienestar Familiar ICBF. Encuesta Nacional de la Situación Nutricional en Colombia, 2005, primera edición. Colombia: Panamericana Formas e Impresos S.A.; 2006.
14. Abella V, Scotece M, Conde J, Lopez V, Pinto J, Gualillo O. Adipocinas, síndrome metabólico y enfermedades reumáticas. J Immunol
Res. 2014; 2014:343-746.
15. Tyrrell PN, Beyene J, Feldman BM, McCrindle BW, Silverman ED, Bradley TJ. Enfermedad carotídea y el grosor intimamedia reumática:
una revisión sistemática y metaanálisis de Arteriosclerosis, Trombosis Biología y Vascular. 2010; 30(5):1014-26.
16. Telles RW, Lanna CCD, Ferreira GA, Ribeiro AL. Metabolic syndrome in patients with systemic lupus erythematosus: association with
traditional risk factors for coronary heart disease and lupus characteristics, Lupus. 2010; 19:803-9.
17. Sabio JM, Zamora-Pasadas M, Jimenez-Jaimez J, Albadalejo J. Vargas H, Rodriguez del Aguila et al. Metabolic syndrome in patients
with systemic lupus erythematosus from Southern Spain. Lupus. 2008; 17:849-59.
18. Parker B, Ahmad Y, Shelmerdine J, Edlin H, et al. An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. Lupus, 2011; 20:1459-65.
19. Bellomio V, Spindler A, Lucero E, et al. Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus. 2009;
18:1019-25.
20. Vizuete B, Salcedo A, Moreno M, Vera C. Association
between Metabolic Syndrome in patients with Systemic Lupus Erythematosus. Departamento de Reumatología de la Consulta Externa del Hospital Luis Vernaza, 2013.
21. Pereira RMR, de Carvalho JF. Síndrome Bonfá E. metabólico en enfermedades reumatológicas. Autoinmunidad Comentarios. 2009; 8 (5): 415-419.
22. Parker B, Urowitz MB, Gladman DD, Lunt M, Bae SC, Sanchez-Guerrero J et al. Clinical associations of the metabolic syndrome in
systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2013; 72:1308-14.
23. Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P et al. High prevalence of the metabolic syndrome in patients with systemic
lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2007; 66:208-
14.
24. Kip KE, Marroquin OC, Kelley DE, Johnson BD, Kelsey SF, Shaw LJ, et al. Clinical importance of obesity versus the metabolic syndrome in
cardiovascular risk in women: a report from theWomen’s Ischemia Syndrome Evaluation (WISE) study. Circulation. 2004; 109:706-13.
25. Cadaval RAM, Martinez JE, Mazzolin MA, Barros RGT et al. Assessment of the risk of coronary heart disease in women with systemic lupus erythematosus. Bras J Rheumatol. 2009; 49(6):658-69.
Downloads
Published
Issue
Section
License
-
Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios<. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
-
NoComercial — No puede utilizar el material para una finalidad comercial.
-
CompartirIgual — Si remezcla, transforma o crea a partir del material, deberá difundir sus contribuciones bajo la misma licencia que el original.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
